What is the current Price Target for the aTyr Pharma, Inc. stock?

The average aTyr Pharma, Inc. target price is $18.87. This is 1,884.23% higher than the current stock price. The highest price target is 3,764.35%, the lowest is 908.94%. 12 Analysts have issued a price target aTyr Pharma, Inc. 2026 .

How high will the aTyr Pharma, Inc. stock rise?

No reliable answer can be given as to how high the aTyr Pharma, Inc. stock will rise. The performance of stocks, including the aTyr Pharma, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the aTyr Pharma, Inc. stock today?

The performance of aTyr Pharma, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the aTyr Pharma, Inc. stock fall?

The decline in aTyr Pharma, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

aTyr Pharma, Inc. Forecast, price target & analysts

$0.92

3.67% today

Nasdaq, Sep 25, 05:47 pm CET

ISIN

US0021201035

Symbol

ATYR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

aTyr Pharma, Inc. Target price 2025 - Analyst rating & recommendation

aTyr Pharma, Inc. Classifications & Recommendation:

Buy

94%

Hold

aTyr Pharma, Inc. Price Target

Target Price	$18.87
Price	$0.95
Potential	1,884.23% register free of charge
Number of Estimates	12

	12 Analysts have issued a price target aTyr Pharma, Inc. 2026 . The average aTyr Pharma, Inc. target price is $18.87. This is 1,884.23% register free of charge higher than the current stock price. The highest price target is $36.75 3,764.35% register free of charge , the lowest is $9.60 908.94% register free of charge .
	A rating was issued by 17 analysts: 16 Analysts recommend aTyr Pharma, Inc. to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the aTyr Pharma, Inc. stock has an average upside potential 2026 of 1,884.23% register free of charge . Most analysts recommend the aTyr Pharma, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-0.86	-0.75
	8.51%	12.79%
P/E		negative
EV/Sales		11.45

13 Analysts have issued a aTyr Pharma, Inc. forecast for earnings per share. The average aTyr Pharma, Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-0.86	8.51%
2025	$-0.75 12.79% Unlock
2026	$-0.66 12.00% Unlock
2027	$-0.10 84.85% Unlock
2028	$1.17 1,270.00% Unlock
2029	$2.90 147.86% Unlock
2030	$4.36 50.34% Unlock
2031	$4.19 3.90% Unlock
2032	$5.06 20.76% Unlock

Current	-1.30	42.74%
2025	-1.27 2.51% Unlock
2026	-1.45 14.17% Unlock
2027	-9.64 564.83% Unlock
2028	0.81 108.40% Unlock
2029	0.33 59.26% Unlock
2030	0.22 33.33% Unlock
2031	0.23 4.55% Unlock
2032	0.19 17.39% Unlock

aTyr Pharma, Inc....

Current aTyr Pharma, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
RBC Capital	Locked ➜ Locked	Locked	Sep 16 2025
Wells Fargo	Locked ➜ Locked	Locked	Sep 16 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Sep 15 2025
Jefferies	Locked ➜ Locked	Locked	Aug 22 2025
Wells Fargo	Locked ➜ Locked	Locked	Jun 20 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jun 04 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	May 19 2025

Analyst Rating	Date
Locked RBC Capital: Locked ➜ Locked	Sep 16 2025
Locked Wells Fargo: Locked ➜ Locked	Sep 16 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Sep 15 2025
Locked Jefferies: Locked ➜ Locked	Aug 22 2025
Locked Wells Fargo: Locked ➜ Locked	Jun 20 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Jun 04 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	May 19 2025

Discover more stocks with a high price target

Novo Nordisk 41.24%

TUI 41.10%

BioNTech SE - ADR 40.09%

Deutsche Telekom 35.71%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now